Measuring and Monitoring Blood Glucose Levels Utilizing Non-invasive Blood Glucose Monitoring Device
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01508065|
Recruitment Status : Recruiting
First Posted : January 11, 2012
Last Update Posted : February 20, 2019
Adequate glycemic control in patients with Diabetes Mellitus (DM) is a desired therapeutic goal that can be achieved with a true non-invasive device offering the likelihood of continuous glucose monitoring. Currently, glucose is best monitored by measuring capillary blood from the fingertips, from venous/arterial line blood samples and from a daily calibrated Subcutaneous Blood Glucose Monitor (SBGM) which is a source of severe inconvenience and hence, a lack of compliance.
Thus, the need for non-invasive and easy to operate glucose monitoring in DM patients for strict glycemic control cannot be overemphasized.
The Glucometer CGM-305 blood glucose readings are accurate and measure blood glucose with an acceptable mean relative error when compared to acceptable invasive blood glucose measurements.
The primary objectives of the trial are to determine:
- The safety of the Glucometer CGM-305 in evaluating blood glucose levels
- The accuracy of the Glucometer CGM-305 in evaluating blood glucose levels
|Condition or disease||Intervention/treatment|
|Diabetes Mellitus Type 1||Device: Glucometer CGM-305|
|Study Type :||Observational|
|Estimated Enrollment :||20 participants|
|Official Title:||Measuring and Monitoring Blood Glucose Levels Utilizing Non-invasive Blood Glucose Monitoring Device|
|Study Start Date :||September 2012|
|Actual Primary Completion Date :||July 2014|
|controlled type one diabetes mellitus.||
Device: Glucometer CGM-305
The study procedure consists of three days trial. After each experimental day the results of blood glucose level reading from the non-invasive Glucometer CGM-305 will be compared to the reading from several devices, as following: Abbott Freestyle Libre, the hexokinase assay (YSI 2300 STAT Plus) from the venous and the laboratory blood measurements. First day of trial consists of 8-10 hours and is used to calibrate the non-invasive Glucometer CGM-305 for the specific patient. During the second and third days a fasting experiment is performed and consists of 4-6 hours.
- Accuracy of the Glucometer CGM-305 blood glucose readings as evaluated by mean relative error when compared to venous blood glucose measured by a laboratory device. [ Time Frame: will be assessed after second experimental day ]
- Accuracy of the Glucometer CGM-305 blood glucose readings as evaluated by correlation with values measured by glucose hexokinase based assay [ Time Frame: will be assessed after second experimental day ]
- Accuracy of the Glucometer CGM-305 blood glucose readings as evaluated by Clark error grid with measurements of venous blood as the comparing value [ Time Frame: will be assessed after second experimental day ]
- The safety of the Glucometer CGM-305 in evaluating blood glucose levels [ Time Frame: The study consists of three days trial, first day lasts an 8-10 hours, second and third days last 4-6 hours. ]
Safety will be evaluated in a descriptive manner by recording all adverse events in the patient population by number and severity.
The study will evaluate safety by assessing:
- Device related adverse events: local and systemic effects of the Glucometer CGM-305 including: redness, burns, pain , or other complications.
- General adverse events: Adverse events not directly related to the Glucometer CGM-305 device but are related to the study procedure (i.e clamping), such as: local infection, blood clot, bleeding, hypoglycemia.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01508065
|Contact: Hadas Lamberg, PhD||00 972 2 email@example.com|
|Hadassah Medical Organization||Recruiting|
|Jerusalem, Israel, 91120|
|Hadassah Medical Organization||Not yet recruiting|